<DOC>
	<DOCNO>NCT00784537</DOCNO>
	<brief_summary>The purpose study define improvement patient : - To evaluate patient resistant initial treatment residual PET-positive mass first two course ABVD ( PET-2 positive ) , salvage early shift high-dose chemotherapy support stem cell rescue - To analyse patient achieve early complete response ( PET-2 negative ) , spar adjuvant radiotherapy area initial bulky disease , end plan six course ABVD . To answer question , PET-2 negative patient randomize radiotherapy versus radiotherapy end ABVD therapy .</brief_summary>
	<brief_title>High-dose Chemotherapy Stem Cell Transplantation , Patients PET-2 Positive , After 2 Courses ABVD Comparison RT Versus RT PET-2 Negative Patients</brief_title>
	<detailed_description>This study compose two phase : 1 . A phase II multi-centre study evaluate patient advanced stage Hodgkin lymphoma efficacy early salvage treatment high-dose chemotherapy follow stem cell transplantation patient FDG-PET positive two course ABVD ( PET-2 positive ) . 2 . A phase III randomise study compare efficacy radiotherapy area initial bulky disease versus therapy PET-2 negative patient complete remission ( PET-6 negative ) end six course ABVD .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Histologically confirm Hodgkin 's lymphoma classical type ( nodular lymphocyte predominance exclude ) . Stage IIBIV . Age 1870 . No prior therapy Hodgkin 's lymphoma Written inform consent . ECOG performance status grade 03 ( see Appendix E ) . FDGPET scan initiation treatment . Prior therapy Hodgkin 's lymphoma . Age less 18 70 . Other concomitant prior malignancy , except basal cell skin carcinoma , adequately treat carcinoma situ cervix , cancer complete remission 5 year . HIV infection . Pregnancy breastfeed . Renal failure ( creatinine ≥2 time normal value ) , liver failure ( AST/ALT bilirubine ≥ 2.5 time normal value ) heart failure ( NYHA class ≥ 2 FEV &lt; 45 % ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>ABVD</keyword>
	<keyword>FDG-PET ( 18-Fluoro-deoxy-D-glucose Positron Emission Tomography )</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>